Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer

Breast

Volumn 20, Issue 3, 2011, Pages 254-258

  Haroun, Iman ^a   Graham, Tracy ^a   Poll, Aletta ^b   Sun, Ping ^b   Hill, Kimberley ^a   Weitzner, Eleanor ^c   Narod, Steven ^b,d   Warner, Ellen ^a,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1; BRCA2; Mastectomy; MRI; Surveillance

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; ATTITUDE TO ILLNESS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; FEAR; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; INTERMETHOD COMPARISON; MASTECTOMY; MOTIVATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PATIENT SATISFACTION; PRIORITY JOURNAL; RISK REDUCTION; WOMEN'S HEALTH;

EID: 79957699302     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.01.006     Document Type: Article

References (19)

1. Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1 mutation carriers. Lancet 1994, 343:692-695.
2. Warner E., Messersmit H., Causer P., Eisen A., Shumak R., Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Int Med 2008, 148:671-679.
3. Gronwald J., Tung N., Foulkes W.D., Offit K., Gershoni R., Daly M., et al. Hereditary breast cancer clinical study group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118:2281-2284.
4. Eisen A., Lubinski J., Klijn J., Moller P., Lynch H.T., Offit K., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23:7491-7496.
5. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van 't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004, 22:1055-1062.
6. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633-1637.
7. Antill Y., Reynolds J., Young M.A., Kirk J., Tucker K., Bogtstra T., et al. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 2006 Mar, 42(5):621-628. Epub 2006 Jan 24.
8. Howard A.F., Bottroff J.L., Balneaves L.G., Kim-Sing C. Women's constructions of the " right time" to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy. BMC Womens Health 2010 Aug 5, 10:24.
9. Hatcher M.B., Fallowfield L., A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ 2001, 322:76.
10. Metcalfe K.A., Semple J.L., Narod S.A. Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study. Plast Reconstr Surg 2004, 114:360-366.
11. Hoogerbrugge N., Kamm Y.J.L., Bult P., Landsbergen K.M., Bongers E.M., Brunner H.G., et al. The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Ann Oncol 2008, 19(4):655-659.
12. Metcalfe K.A., Lubinski J., Ghadirian P., Lynch H., Kim- Sing C., Friedman E., et al. Predictors of contralateral mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group. JCO 2008, 26(7):1093-1097.
13. Hamilton R., Williams J.K., Bowers B.J., Calzone K. Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer. J Genet Couns 2009 Apr, 18(2):147-159. Epub 2008 Nov 1.
14. Unic I., Verhoef L.C., Stalmeier P., van Daal W.A. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical decision-analytic recommendations. Med Decis Making 2000 Jul-Sep, 20(3):251-262.
15. Friebel T.M., Domchek S.M., Neuhausen S.L., Wagner T., Evans D.G., Isaacs C., et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 2007 Dec, 7(11):875-882.
16. McCullum M., Bottorff J.L., Kelly M., Kieffer S.A., Balneaves L.G. Time to decide about risk-reducing mastectomy: a case series of BRCA1/2 gene mutation carriers. BMC Womens Health 2007 Mar 6, 7:3.
17. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333.
18. Ozanne E.M., Wittenberg E., Garber J.E., Weeks J.C. Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J 2010 Jan, 16(1):38-47.
19. Zikmund-Fisher B.J., Ubel P.A., Smith D.M., Derry H.A., McClure J.B., Stark A., et al. Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs. Patient Educ Couns 2008 Nov, 73(2):209-214.